DECODE COMPLETES CLINICAL PROGRAM FOR DG041
deCODE genetics has announced top-line results from Phase I clinical studies of DG041, the company's developmental compound for the treatment of peripheral artery disease.
To date, a total of 196 healthy subjects have been exposed to DG041 at doses up to 1600 mg per day for seven days. DG041 was found to be well-tolerated at all dose levels tested, with no drug-related serious adverse events noted. DG041 provided a dose-dependent reduction in platelet aggregation after stimulation with collagen and sulprostone, an agonist of prostaglandins E2.